STOCK TITAN
  1. Home
  2. News
  3. RPRX

Royalty Pharma plc - RPRX STOCK NEWS

Welcome to our dedicated news page for Royalty Pharma plc (Ticker: RPRX), a resource for investors and traders seeking the latest updates and insights on Royalty Pharma plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Royalty Pharma plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Royalty Pharma plc's position in the market.

News
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) will announce its first quarter 2024 financial results on May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Royalty Pharma Declares Second Quarter 2024 Dividend
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) has declared a dividend of $0.21 per Class A ordinary share for the second quarter of 2024. The dividend payment is scheduled for June 14, 2024, for shareholders of record as of May 17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends earnings
-
News
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
Rhea-AI Summary
Royalty Pharma plc (RPRX) will participate in a fireside chat at TD Cowen’s 44th Annual Health Care Conference on March 5, 2024, at 10:30 a.m. ET. The webcast will be available on Royalty Pharma’s website and archived for at least thirty days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences
News
Royalty Pharma Reports Q4 and Full Year 2023 Results
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) reported strong financial results for Q4 2023 and FY 2023, with Portfolio Receipts of $736 million and $3,049 million respectively. The company announced transactions of up to $4.0 billion in 2023 and introduced full year 2024 guidance with expected Portfolio Receipts of $2,600 to $2,700 million, reflecting royalty receipts growth of 5% to 9% year/year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
earnings
-
News
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
Rhea-AI Summary
Royalty Pharma plc (RPRX) is set to report its fourth quarter and full year 2023 financial results on February 15, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time. Investors can access the conference call information and live webcast on the company's website. A replay will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
earnings
-
News
Royalty Pharma Announces Dividend Increase
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, marking a 5% increase from the previous quarter. The dividend will be paid on March 15, 2024, to shareholders of record as of February 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
dividends
News
Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on MSCI Inc. (NYSE: MSCI)
Rhea-AI Summary
Spruce Point Capital Management, a New York-based investment management firm, has issued a report outlining concerns about MSCI Inc. (NYSE: MSCI). The report expresses concerns about the company's business segments, accounting practices, and recent acquisitions. It also highlights client retention challenges, declining cash flow, and plunging dividend growth rates. The report notes a pattern of opaque deal-making and questions whether they are in the best interest of shareholders. Spruce Point believes MSCI exhibits long-term downside risk and recommends underweighting MSCI's stock relative to the S&P 500.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
News
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Royalty Pharma plc (Nasdaq: RPRX) expects 2023 Portfolio Receipts to exceed $3,050 million, showing double-digit growth since its 2020 IPO. The company added $13 billion in transactions since 2020, aiming to add $1.2 billion to Portfolio Receipts in 2025. They anticipate significant capital deployment and increased funding for healthcare innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
none
-
News
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
Rhea-AI Summary
Royalty Pharma plc (RPRX) to participate in fireside chat at Evercore ISI 6th Annual HealthCONx Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
conferences
News
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) collaborates with Royalty Pharma plc (Nasdaq: RPRX) to accelerate the clinical research program for olanzapine LAI (TEV-‘749) by receiving up to $125 million in funding. Olanzapine LAI is a long-acting subcutaneous injectable olanzapine for schizophrenia currently in Phase 3. The collaboration aims to support the development of this potential first long-acting olanzapine with a favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
none
Stock RPRX logo
Royalty Pharma plc

Nasdaq:RPRX

RPRX Rankings

#685 Ranked by Market Cap
#4238 Ranked by Stock Gains
#1133 Ranked by Dividends

RPRX Stock Data

16.86B
383.82M
3.83%
72.1%
2.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About RPRX

royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma’s strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott’s humira®, j&j/merck’s remi